Joanna Schaenman

Dr. Joanna Schaenman


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
DFDiana F. Florescu
Diana F. Florescu
JSJoanna Schaenman
Joanna Schaenman
OPon behalf of the AST Infectious Diseases Community of Practice
on behalf of the AST Infectious Diseases Community of Practice

1 September 2018 in Human Immunology
Verified
Journal Article
Closed access
JSJoanna Schaenman
Joanna Schaenman
MRM. Rossetti
M. Rossetti
TST. Sidwell
T. Sidwell
VGV. Groysberg
V. Groysberg
GSG. Sunga
G. Sunga
ERE.F. Reed
E.F. Reed

1 June 2017 in Transplantation
Verified
Journal Article
Closed access
JSJoanna Schaenman
Joanna Schaenman
YKYael Korin
Yael Korin
TSTiffany Sidwell
Tiffany Sidwell
FKFadi Kandarian
Fadi Kandarian
NHNicholas Ba Harre
Nicholas Ba Harre
ERElaine F. Reed
Elaine F. Reed
Background BK virus infection remains an important cause of loss of allograft function after kidney transplantation. We sought to determine whether polyfunctional T cells secreting multiple cytokines simultaneously, which have been shown to be associated with viral control, could be detected early after start of BK viremia, which would provide insight into the mechanism of successful antiviral control. Methods Peripheral blood mononuclear cells collected during episodes of BK viral replication were evaluated by multiparameter flow cytometry after stimulation by overlapping peptide pools of BK virus antigen to determine frequency of CD8+ and CD4+ T cells expressing 1 or more cytokines simultaneously, as well as markers of T-cell activation, exhaustion, and maturation. Results BK virus controllers, defined as those with episodes of BK viremia of 3 months or less, had an 11-fold increase in frequency of CD8+ polyfunctional T cells expressing multiple cytokines, as compared with patients with prolonged episodes of BK viremia. Patients with only low level BK viremia expressed low frequencies of polyfunctional T cells. Polyfunctional T cells were predominantly of the effector memory maturation subtype and expressed the cytotoxicity marker CD107a. Conclusions Noninvasive techniques for immune assessment of peripheral blood can provide insight into the mechanism of control of BK virus replication and may allow for future patient risk stratification and customization of immune suppression at the onset of BK viremia.

24 December 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
JSJoanna Schaenman
Joanna Schaenman
JDJoshua M. Diamond
Joshua M. Diamond
JGJohn Greenland
John Greenland
CGCynthia Gries
Cynthia Gries
CKCassie C. Kennedy
Cassie C. Kennedy
SBSangeeta Bhorade
Sangeeta Bhorade
Many lung transplant candidates and recipients are older and frailer compared to previous eras. Older patients are at increased risk for pre- and posttransplant mortality, but this risk is not explained by numerical age alone. This manuscript represents the product of the American Society of Transplantation (AST) conference on frailty. Experts in the field reviewed the latest published research on assessment of elderly and frail lung transplant candidates. Physical frailty, often defined as slowness, weakness, low physical activity, shrinking, and exhaustion, and frailty evaluation is an important tool for evaluation of age-associated dysfunction. Another approach is assessment by cumulative deficits, and both types of frailty are common in lung transplant candidates. Frailty is associated with death or delisting before transplant, and may be associated with posttransplant mortality. Sarcopenia, cognitive dysfunction, depression, and nutrition are other important components for patient evaluation. Aging-associated inflammation, telomere dysfunction, and adaptive immune system senescence may also contribute to frailty. Developing tools for frailty assessment and interventions holds promise for improving patient outcomes before and after lung transplantation.

8 November 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
HPHarry Pickering
Harry Pickering
SSSubha Sen
Subha Sen
JAJanice Arakawa-Hoyt
Janice Arakawa-Hoyt
KIKenichi Ishiyama
Kenichi Ishiyama
YSYumeng Sun
Yumeng Sun
ERElaine F. Reed
Elaine F. Reed
CMV causes mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals can be life-threatening. CMV viremia often occurs in solid organ transplant recipients and associates with decreased graft survival and higher mortality. Furthering understanding of impaired immunity that allows CMV reactivation is critical to guiding antiviral therapy and examining the effect of CMV on solid organ transplant outcomes. This study characterized longitudinal immune responses to CMV in 31 kidney transplant recipients with CMV viremia and matched, nonviremic recipients. Recipients were sampled 3 and 12 months after transplant, with additional samples 1 week and 1 month after viremia. PBMCs were stained for NK and T cell markers. PBMC transcriptomes were characterized by RNA-Seq. Plasma proteins were quantified by Luminex. CD8 + T cell transcriptomes were characterized by single-cell RNA-Seq. Before viremia, patients had high levels of IL-15 with concurrent expansion of immature CD56 bright NK cells. After viremia, mature CD56 dim NK cells and CD28 – CD8 + T cells upregulating inhibitory and NK-associated receptors were expanded. Memory NK cells and NK-like CD28 – CD8 + T cells were associated with control of viremia. These findings suggest that signatures of innate activation may be prognostic for CMV reactivation after transplant, while CD8 + T cell functionality is critical for effective control of CMV.

30 May 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
MSMichael Y. Shino
Michael Y. Shino
JTJamie L. Todd
Jamie L. Todd
MNMegan L. Neely
Megan L. Neely
JKJerry Kirchner
Jerry Kirchner
CFCourtney W. Frankel
Courtney W. Frankel
JBJohn A. Belperio
John A. Belperio
Histopathologic lung allograft injuries are putative harbingers for chronic lung allograft dysfunction (CLAD). However, the mechanisms responsible are not well understood. CXCL9 and CXCL10 are potent chemoattractants of mononuclear cells and potential propagators of allograft injury. We hypothesized that these chemokines would be quantifiable in plasma, and would associate with subsequent CLAD development. In this prospective multicenter study, we evaluated 721 plasma samples for CXCL9/CXCL10 levels from 184 participants at the time of transbronchial biopsies during their first-year post-transplantation. We determined the association between plasma chemokines, histopathologic injury, and CLAD risk using Cox proportional hazards models. We also evaluated CXCL9/CXCL10 levels in bronchoalveolar lavage (BAL) fluid and compared plasma to BAL with respect to CLAD risk. Plasma CXCL9/CXCL10 levels were elevated during the injury patterns associated with CLAD, acute rejection, and acute lung injury, with a dose-response relationship between chemokine levels and CLAD risk. Importantly, there were strong interactions between injury and plasma CXCL9/CXCL10, where histopathologic injury associated with CLAD only in the presence of elevated plasma chemokines. We observed similar associations and interactions with BAL CXCL9/CXCL10 levels. Elevated plasma CXCL9/CXCL10 during allograft injury may contribute to CLAD pathogenesis and has potential as a minimally invasive immune monitoring biomarker.